Scientists have harnessed the revolutionary CRISPR technology, originally an immune system bacteria use to defend against viruses, to edit genetic information within cells. The FDA recently approved the first CRISPR-based therapeutic in December 2023, specifically designed to treat sickle cell disease using the well-studied CRISPR-Cas9 genetic scissor system.
While CRISPR-Cas9 has paved the way for gene editing, a newer and promising platform, Type I CRISPR or CRISPR-Cas3, with the potential for large-sized DNA removals, is emerging for potential therapeutic use.
Continue reading… “Enhancing CRISPR-Cas3 Safety: Scientists Develop Off-Switches for Precise Genome Editing”